ATRX (Adhera Therapeutics) Short-Term Debt: $10.83 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRX Adhera Therapeutics Inc ATRX
12 GF Score
Price $0.00
View Full Analysis

What is Adhera Therapeutics Short-Term Debt?

Adhera Therapeutics ATRX 12 Short-Term Debt is $10.83 Mil as of Sep. 2023. GuruFocus rates ATRX with a GF Score™ of 12/100.

Adhera Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2023 was $10.83 Mil.

Adhera Therapeutics's quarterly Short-Term Debt increased from Mar. 2023 ($9.63 Mil) to Jun. 2023 ($10.59 Mil) and increased from Jun. 2023 ($10.59 Mil) to Sep. 2023 ($10.83 Mil).

Adhera Therapeutics's annual Short-Term Debt increased from Dec. 2020 ($6.32 Mil) to Dec. 2021 ($6.66 Mil) and increased from Dec. 2021 ($6.66 Mil) to Dec. 2022 ($8.59 Mil).

Adhera Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Adhera Therapeutics Short-Term Debt Related Terms

Adhera Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Adhera Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Short-Term Debt Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 5.33 6.32 6.66 8.59

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.99 8.59 9.63 10.59 10.83
ATRX
12GF Score
Adhera Therapeutics Inc ATRX
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $10.83 Mil mean?
Adhera Therapeutics (ATRX) has a Short-Term Debt of $10.83 Mil as of Sep. 2023.
Is Adhera Therapeutics' Short-Term Debt too high?
Adhera Therapeutics' current Short-Term Debt is $10.83 Mil. Overall, Adhera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Adhera Therapeutics' Short-Term Debt compare to PKBO and ARDS?
Adhera Therapeutics' Short-Term Debt of $10.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Adhera Therapeutics's current Short-Term Debt is $10.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adhera Therapeutics stock overvalued right now?
Adhera Therapeutics (ATRX) has a current Short-Term Debt of $10.83 Mil. The current Short-Term Debt is $10.83 Mil. Adhera Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Adhera Therapeutics (ATRX), the current Short-Term Debt is $10.83 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adhera Therapeutics Business Description

Address 8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score

Get the complete analysis for ATRX

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price